CN1917902A - 白细胞介素-33(il-33)和il-33受体复合物的用途 - Google Patents
白细胞介素-33(il-33)和il-33受体复合物的用途 Download PDFInfo
- Publication number
- CN1917902A CN1917902A CNA2005800050705A CN200580005070A CN1917902A CN 1917902 A CN1917902 A CN 1917902A CN A2005800050705 A CNA2005800050705 A CN A2005800050705A CN 200580005070 A CN200580005070 A CN 200580005070A CN 1917902 A CN1917902 A CN 1917902A
- Authority
- CN
- China
- Prior art keywords
- leu
- ser
- val
- arg
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54573004P | 2004-02-17 | 2004-02-17 | |
| US60/545,730 | 2004-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1917902A true CN1917902A (zh) | 2007-02-21 |
Family
ID=34886190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800050705A Pending CN1917902A (zh) | 2004-02-17 | 2005-02-15 | 白细胞介素-33(il-33)和il-33受体复合物的用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20050203046A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1725261B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP4949859B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1917902A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE496636T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005215528B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0507808A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2555236C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602005026105D1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20064193L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ549040A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI372628B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005079844A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200606844B (cg-RX-API-DMAC7.html) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105007929A (zh) * | 2013-03-15 | 2015-10-28 | 瑞泽恩制药公司 | Il-33拮抗剂和其用途 |
| CN105051063A (zh) * | 2013-03-13 | 2015-11-11 | 瑞泽恩制药公司 | 抗-il-33抗体及其用途 |
| CN105980556A (zh) * | 2013-12-26 | 2016-09-28 | 田边三菱制药株式会社 | 人抗il-33中和单克隆抗体 |
| CN107109494A (zh) * | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | Il‑33介导型疾病的治疗方法和诊断方法 |
| CN108064236A (zh) * | 2015-03-31 | 2018-05-22 | 免疫医疗有限公司 | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 |
| CN108137682A (zh) * | 2015-10-06 | 2018-06-08 | 瑞泽恩制药公司 | 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途 |
| CN109863173A (zh) * | 2016-10-28 | 2019-06-07 | 伊莱利利公司 | 抗-il-33抗体及其用途 |
| CN111012905A (zh) * | 2013-10-07 | 2020-04-17 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
| CN111979198A (zh) * | 2013-03-15 | 2020-11-24 | 伊利克斯根治疗公司 | 使用zscan4复壮人细胞的方法 |
| CN112210556A (zh) * | 2020-10-15 | 2021-01-12 | 扬州大学 | 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用 |
| CN116396974A (zh) * | 2022-02-21 | 2023-07-07 | 吉林农业大学 | 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用 |
| US11725050B2 (en) | 2014-11-10 | 2023-08-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US11834505B2 (en) | 2016-06-29 | 2023-12-05 | Checkpoint Therapeutics, Inc. | PD-L1-specific antibodies and methods of using the same |
| WO2025082552A3 (zh) * | 2023-10-16 | 2025-05-30 | 王琪 | 负载il33的溶瘤痘苗病毒及其与免疫检查点抑制剂的联合疗法 |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| ES2375181T3 (es) | 2002-05-09 | 2012-02-27 | The Brigham And Women's Hospital, Inc. | 1l 1rl-1 como un marcador de enfermedades cardiovasculares. |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2009511572A (ja) * | 2005-10-16 | 2009-03-19 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 炎症性皮膚疾患、障害または症状のための医薬組成物および診断方法 |
| PL2386860T4 (pl) * | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Przewidywanie śmiertelności i wykrywanie poważnej choroby |
| ATE517341T1 (de) * | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen |
| DK2482078T3 (en) | 2006-05-01 | 2016-05-02 | Critical Care Diagnostics Inc | Cardiovascular disease diagnosis |
| SI2019965T1 (sl) * | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics, Inc. | Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja |
| WO2007130627A2 (en) * | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| SE532250C2 (sv) * | 2006-11-28 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| JP2010527936A (ja) * | 2007-05-18 | 2010-08-19 | メディミューン,エルエルシー | 炎症性疾患におけるil−33 |
| PT3093663T (pt) | 2008-04-18 | 2018-10-19 | Critical Care Diagnostics Inc | Previsão do risco de eventos cardíacos adversos maiores |
| JP5539660B2 (ja) * | 2009-03-10 | 2014-07-02 | 公益財団法人ヒューマンサイエンス振興財団 | 粘膜ワクチン用アジュバント |
| EP2475388B1 (en) * | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| ES2549637T3 (es) * | 2011-02-23 | 2015-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos contra IL33R humano y la utilización de los mismos |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| IN2015DN01767A (cg-RX-API-DMAC7.html) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| US10703799B2 (en) | 2012-12-10 | 2020-07-07 | Vib Vzw | IL-33R and IL-1RAcP fusion proteins |
| WO2014126277A1 (ko) * | 2013-02-14 | 2014-08-21 | 건국대학교 산학협력단 | 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도 |
| WO2014128254A1 (en) * | 2013-02-22 | 2014-08-28 | University Of Eastern Finland (Kuopion Kampus) | Il-33 and treatment of neurodegenerative diseases |
| US9840545B2 (en) | 2013-09-20 | 2017-12-12 | University Of Virginia Patent Foundation | Fusion protein comprising interleukin-2 and interleukin-33 |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| WO2016140921A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| WO2016138590A1 (en) * | 2015-03-03 | 2016-09-09 | Wilfred Jefferies | Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44 |
| JP6501650B2 (ja) * | 2015-06-25 | 2019-04-17 | 田辺三菱製薬株式会社 | ヒト抗il−33中和モノクローナル抗体 |
| US10813979B2 (en) * | 2015-07-10 | 2020-10-27 | The Hong Kong University Of Science And Technology | Methods and compositions for treating neurodegenerative and neuroinflammatory conditions |
| KR101765397B1 (ko) | 2015-12-02 | 2017-08-07 | 한국과학기술원 | 질점막을 통한 바이러스 감염 취약 진단 마커로서의 il-33의 용도 |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CN116715775A (zh) | 2017-02-10 | 2023-09-08 | 豪夫迈·罗氏有限公司 | 抗类胰蛋白酶抗体、其组合物及其用途 |
| EP3582802A4 (en) * | 2017-02-17 | 2021-02-17 | The General Hospital Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A BRAIN INJURY |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| KR102872720B1 (ko) | 2017-05-05 | 2025-10-16 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 기질 결합 소낭의 안구에의 적용 |
| WO2019045075A1 (ja) | 2017-08-31 | 2019-03-07 | 田辺三菱製薬株式会社 | Il-33アンタゴニストを含む子宮内膜症治療剤 |
| KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| IL307286B2 (en) | 2018-04-11 | 2026-03-01 | Regeneron Pharma | Methods and compositions for quantifying il-33 |
| EP3787642A4 (en) * | 2018-05-03 | 2022-09-21 | University of Pittsburgh - of the Commonwealth System of Higher Education | IL-33 CONTAINING MATRIX-BONDED VESICLES (MBVS) AND THEIR USE |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| WO2020047333A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CA3109139A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| TWI861073B (zh) | 2019-03-21 | 2024-11-11 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| WO2021003138A1 (en) * | 2019-06-30 | 2021-01-07 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treatment of pancreatic cancer |
| WO2021068196A1 (en) * | 2019-10-11 | 2021-04-15 | General Regeneratives (Shanghai) Limited | Methods of using il-33 protein in treating cancers |
| JP7843701B2 (ja) * | 2019-11-04 | 2026-04-10 | メディミューン リミテッド | Il-33アンタゴニストの使用方法 |
| CN116670163A (zh) | 2020-02-11 | 2023-08-29 | Hcw生物科技公司 | 治疗年龄相关疾病和炎性疾病的方法 |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| AU2021262794B2 (en) | 2020-04-29 | 2026-06-18 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods for treating disorders related to aging |
| WO2022164976A2 (en) * | 2021-01-27 | 2022-08-04 | The Trustees Of Dartmouth College | Immunostimulatory cytokine combination and therapeutic use thereof |
| WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US12594323B2 (en) | 2022-04-13 | 2026-04-07 | Immunitybio, Inc. | Methods of reducing neuroinflammation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
| WO1992010210A1 (en) * | 1990-12-14 | 1992-06-25 | E.I. Du Pont De Nemours And Company | Inhibition of angiogenesis by il-1 |
| US5856457A (en) | 1991-03-29 | 1999-01-05 | Genentech, Inc. | Nucleic acids encoding a human IL-8 receptor |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US5576191A (en) * | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5888530A (en) | 1995-07-21 | 1999-03-30 | The General Hospital Corporation | Method of enhancing delivery of a pharmaceutical formulation |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
| ATE406441T1 (de) | 1997-10-29 | 2008-09-15 | Genentech Inc | Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1 |
| WO1999032626A1 (en) * | 1997-12-23 | 1999-07-01 | Immunex Corporation | Sigirr dna and polypeptides |
| GB9727172D0 (en) * | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| CA2340579A1 (en) | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| US6323334B1 (en) * | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001046697A2 (en) | 1999-12-21 | 2001-06-28 | Millennium Predictive Medicine | Identification, assessment, prevention, and therapy of breast cancer |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| CA2431861A1 (en) | 2000-12-08 | 2002-06-13 | Curagen Corporation | Method of detecting and treating tuberous sclerosis complex associated disorders |
| US20040009481A1 (en) * | 2001-06-11 | 2004-01-15 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| AU2001289843A1 (en) | 2001-08-28 | 2002-02-13 | Bayer Cropscience Ag | Polypeptides for identifying herbicidally active compounds |
| AU2003299441A1 (en) * | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
| EP1759010A4 (en) | 2004-01-07 | 2008-12-24 | Bristol Myers Squibb Co | BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| JP2010527936A (ja) | 2007-05-18 | 2010-08-19 | メディミューン,エルエルシー | 炎症性疾患におけるil−33 |
-
2004
- 2004-11-29 NZ NZ549040A patent/NZ549040A/xx not_active IP Right Cessation
-
2005
- 2005-02-15 CA CA2555236A patent/CA2555236C/en not_active Expired - Lifetime
- 2005-02-15 JP JP2006553342A patent/JP4949859B2/ja not_active Expired - Lifetime
- 2005-02-15 EP EP05713577A patent/EP1725261B1/en not_active Expired - Lifetime
- 2005-02-15 AU AU2005215528A patent/AU2005215528B2/en not_active Ceased
- 2005-02-15 CN CNA2005800050705A patent/CN1917902A/zh active Pending
- 2005-02-15 AT AT05713577T patent/ATE496636T1/de not_active IP Right Cessation
- 2005-02-15 US US11/059,117 patent/US20050203046A1/en not_active Abandoned
- 2005-02-15 WO PCT/US2005/004743 patent/WO2005079844A2/en not_active Ceased
- 2005-02-15 EP EP10177117.8A patent/EP2283860A3/en not_active Withdrawn
- 2005-02-15 BR BRPI0507808-3A patent/BRPI0507808A/pt not_active IP Right Cessation
- 2005-02-15 DE DE602005026105T patent/DE602005026105D1/de not_active Expired - Lifetime
- 2005-02-16 TW TW094104561A patent/TWI372628B/zh not_active IP Right Cessation
- 2005-02-16 TW TW101117025A patent/TW201304802A/zh unknown
-
2006
- 2006-08-15 ZA ZA200606844A patent/ZA200606844B/xx unknown
- 2006-09-15 NO NO20064193A patent/NO20064193L/no not_active Application Discontinuation
-
2007
- 2007-03-05 US US11/682,224 patent/US20070160579A1/en not_active Abandoned
-
2008
- 2008-09-26 US US12/239,689 patent/US20090041718A1/en not_active Abandoned
-
2011
- 2011-06-13 JP JP2011131646A patent/JP2011178810A/ja active Pending
-
2014
- 2014-02-03 US US14/171,629 patent/US9970944B2/en active Active
- 2014-02-20 JP JP2014030239A patent/JP2014098026A/ja active Pending
-
2015
- 2015-08-21 JP JP2015163939A patent/JP2016034948A/ja active Pending
-
2017
- 2017-12-20 US US15/848,417 patent/US20180128837A1/en not_active Abandoned
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105051063A (zh) * | 2013-03-13 | 2015-11-11 | 瑞泽恩制药公司 | 抗-il-33抗体及其用途 |
| CN105051063B (zh) * | 2013-03-13 | 2019-08-16 | 瑞泽恩制药公司 | 抗-il-33抗体及其用途 |
| CN111979198A (zh) * | 2013-03-15 | 2020-11-24 | 伊利克斯根治疗公司 | 使用zscan4复壮人细胞的方法 |
| US12478659B2 (en) | 2013-03-15 | 2025-11-25 | Elixirgen Therapeutics, Inc. | Methods of using ZSCAN4 for rejuvenating human cells |
| US12478657B2 (en) | 2013-03-15 | 2025-11-25 | Elixirgen Therapeutics, Inc. | Methods of using Zscan4 for rejuvenating human cells |
| CN105007929B (zh) * | 2013-03-15 | 2019-05-10 | 瑞泽恩制药公司 | Il-33拮抗剂和其用途 |
| CN105007929A (zh) * | 2013-03-15 | 2015-10-28 | 瑞泽恩制药公司 | Il-33拮抗剂和其用途 |
| CN111012905B (zh) * | 2013-10-07 | 2023-12-22 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
| CN111012905A (zh) * | 2013-10-07 | 2020-04-17 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
| CN105980556A (zh) * | 2013-12-26 | 2016-09-28 | 田边三菱制药株式会社 | 人抗il-33中和单克隆抗体 |
| TWI563003B (en) * | 2013-12-26 | 2016-12-21 | Mitsubishi Tanabe Pharma Corp | Human anti-il-33 neutralization monoclonal antibody |
| CN105980556B (zh) * | 2013-12-26 | 2020-10-09 | 田边三菱制药株式会社 | 人抗il-33中和单克隆抗体 |
| US11725050B2 (en) | 2014-11-10 | 2023-08-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CN107109494A (zh) * | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | Il‑33介导型疾病的治疗方法和诊断方法 |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| CN107109494B (zh) * | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| US11738081B2 (en) | 2015-03-31 | 2023-08-29 | Medimmune Limited | Polynucleotides encoding IL33 antibodies and methods of using the same |
| CN108064236B (zh) * | 2015-03-31 | 2021-12-10 | 免疫医疗有限公司 | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 |
| CN108064236A (zh) * | 2015-03-31 | 2018-05-22 | 免疫医疗有限公司 | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 |
| CN108137682A (zh) * | 2015-10-06 | 2018-06-08 | 瑞泽恩制药公司 | 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途 |
| US11834505B2 (en) | 2016-06-29 | 2023-12-05 | Checkpoint Therapeutics, Inc. | PD-L1-specific antibodies and methods of using the same |
| CN109863173A (zh) * | 2016-10-28 | 2019-06-07 | 伊莱利利公司 | 抗-il-33抗体及其用途 |
| CN109863173B (zh) * | 2016-10-28 | 2022-06-03 | 伊莱利利公司 | 抗-il-33抗体及其用途 |
| CN112210556A (zh) * | 2020-10-15 | 2021-01-12 | 扬州大学 | 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用 |
| CN116396974B (zh) * | 2022-02-21 | 2024-02-13 | 吉林农业大学 | 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用 |
| CN116396974A (zh) * | 2022-02-21 | 2023-07-07 | 吉林农业大学 | 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用 |
| WO2025082552A3 (zh) * | 2023-10-16 | 2025-05-30 | 王琪 | 负载il33的溶瘤痘苗病毒及其与免疫检查点抑制剂的联合疗法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005026105D1 (de) | 2011-03-10 |
| JP2007523089A (ja) | 2007-08-16 |
| EP1725261A2 (en) | 2006-11-29 |
| ZA200606844B (en) | 2008-05-28 |
| BRPI0507808A (pt) | 2007-07-10 |
| EP2283860A3 (en) | 2013-06-05 |
| JP2016034948A (ja) | 2016-03-17 |
| EP1725261B1 (en) | 2011-01-26 |
| US20140140954A1 (en) | 2014-05-22 |
| JP2011178810A (ja) | 2011-09-15 |
| AU2005215528B2 (en) | 2009-04-30 |
| CA2555236A1 (en) | 2005-09-01 |
| TW200539891A (en) | 2005-12-16 |
| JP2014098026A (ja) | 2014-05-29 |
| NO20064193L (no) | 2006-11-16 |
| WO2005079844A3 (en) | 2005-11-24 |
| JP4949859B2 (ja) | 2012-06-13 |
| US20180128837A1 (en) | 2018-05-10 |
| NZ549040A (en) | 2009-07-31 |
| TWI372628B (en) | 2012-09-21 |
| US9970944B2 (en) | 2018-05-15 |
| ATE496636T1 (de) | 2011-02-15 |
| CA2555236C (en) | 2015-05-05 |
| US20090041718A1 (en) | 2009-02-12 |
| US20050203046A1 (en) | 2005-09-15 |
| WO2005079844A2 (en) | 2005-09-01 |
| US20070160579A1 (en) | 2007-07-12 |
| EP2283860A2 (en) | 2011-02-16 |
| AU2005215528A1 (en) | 2005-09-01 |
| TW201304802A (zh) | 2013-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1759123A (zh) | Il-23激动剂及拮抗剂的用途;相关试剂 | |
| AU2005215528B2 (en) | Use for interleukin-33 (IL33) and the IL-33 receptor complex | |
| CN1247780C (zh) | 哺乳动物细胞因子样多肽-10 | |
| CN1125082C (zh) | 人类趋化因子β-8,趋化因子β-1和巨噬细胞炎性蛋白-4 | |
| CN1906297A (zh) | Il-23及其受体、相关试剂和方法 | |
| CN1849131A (zh) | 用白介素-21/白介素-21受体的激动剂治疗免疫性疾病 | |
| CN1575337A (zh) | 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法 | |
| KR20150127185A (ko) | 비글리코실화 Fc-함유 폴리펩티드 | |
| CN1378595A (zh) | 作为zalpha受体之配体的人细胞因子及其用途 | |
| CN1327452A (zh) | 具有肝细胞增殖活性的成纤维细胞生长因子 | |
| EP4385573A2 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| CN1665933A (zh) | 用于治疗肿瘤的免疫缀合物 | |
| CN1589902A (zh) | 抗-LT-β-R抗体在制备药用组合物中的应用 | |
| CN1891714A (zh) | 单纯疱疹病毒进入介体的配体和使用方法 | |
| CN1921886A (zh) | 调节细胞因子活性的方法;相关药剂 | |
| CN1323716C (zh) | Sarp-1在治疗和/或预防硬皮病中的应用 | |
| CN1305529C (zh) | Il-18抑制剂在治疗或预防中枢神经系统损伤中的应用 | |
| CN1195853C (zh) | 神经营养因子nnt-1 | |
| CN1909926A (zh) | 能够结合il-18bp和抑制第二细胞因子活性的细胞因子的用途 | |
| CN1568193A (zh) | Il-18抑制剂在过敏反应疾病中的应用 | |
| CN1634991A (zh) | 人源抗破伤风毒素单克隆抗体及其制备方法和用途 | |
| CN1198842C (zh) | 具有细胞趋化作用和造血刺激活性的趋化素样因子 | |
| CN1230993A (zh) | 制备血小板生成素多肽的表达载体、细胞和方法 | |
| CN1638799A (zh) | 人类肥大细胞表达的膜蛋白 | |
| HK40112585A (en) | Interleukin-2 muteins for the expansion of t-regulatory cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: new jersey Applicant after: Schering Corporation Address before: new jersey Applicant before: SCHERING CORP (US) |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP. |
|
| AD01 | Patent right deemed abandoned | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20170524 |